Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

Guillaume Moulis¹, Frederick Chen², Giuseppe Carli³, Waleed Ghanima⁴, Karolin Trautmann-Grill⁵, Thomas Stauch⁶, Alexandra Schifferli⁷, Haroon Miah², Manuela Rueter⁸, Lisanna Ghiotto⁹, Riccardo Tomasello¹⁰, Annabell Georgi⁵, Vickie McDonald¹¹, Francesco Zaja¹², Heidi Hassel Pettersen¹⁰, Thomas Kühne¹³, Maria Luisa Lozano¹⁴, Tomás José González-López¹⁵, Drew Provan¹⁶, Marc Michel¹⁷, Nichola Cooper¹⁸, Francesco Rodeghiero¹⁹

Affiliations

¹ Department of internal medicine, referral center for autoimmune cytopenias in adults, and Clinical investigation center 1436, Toulouse University hospital, Toulouse, France; European Research Consortium on Immune thrombocytopenia (ERCI), founding member. moulis.g@chu-toulouse.fr.
² ITP Centre and UK Adult ITP registry, Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom and Queen Mary University of London, London.
³ Department of Hematology, San Bortolo Hospital, Vicenza.
⁴ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Østfold hospital, Norway and Institute of clinical medicine, University of Oslo, Oslo.
⁵ Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden.
⁶ Universitätsklinikum Jena, Jena.
⁷ Department of Hematology/Oncology, University Children's Hospital Basel, Basel.
⁸ Department of internal medicine, referral center for autoimmune cytopenias in adults, and Clinical investigation center 1436, Toulouse University hospital, Toulouse.
⁹ Hematology Project Foundation, Affiliated to the Department of Hematology, San Bortolo Hospital, Vicenza.
¹⁰ Østfold hospital, Norway and Institute of clinical medicine, University of Oslo, Oslo.
¹¹ Guy's Hospital, London.
¹² European Research Consortium on Immune thrombocytopenia (ERCI), founding member; DSM, Università degli Studi di Trieste, Trieste.
¹³ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Department of Hematology/Oncology, University Children's Hospital Basel, Basel.
¹⁴ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER, Murcia, Spain.
¹⁵ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hospital Universitario de Burgos, Burgos, Spain.
¹⁶ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; ITP Centre and UK Adult ITP registry, Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom and Queen Mary University of London, London.
¹⁷ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Mondor University Hospital, Créteil.
¹⁸ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Imperial College London, London.
¹⁹ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hematology Project Foundation, Affiliated to the Department of Hematology, San Bortolo Hospital, Vicenza.

PMID: 40568720
DOI: 10.3324/haematol.2025.287408

Free article

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

Guillaume Moulis et al. Haematologica. 2025.

Free article

. 2025 Jun 26.

doi: 10.3324/haematol.2025.287408. Online ahead of print.

Authors

Affiliations

¹ Department of internal medicine, referral center for autoimmune cytopenias in adults, and Clinical investigation center 1436, Toulouse University hospital, Toulouse, France; European Research Consortium on Immune thrombocytopenia (ERCI), founding member. moulis.g@chu-toulouse.fr.
² ITP Centre and UK Adult ITP registry, Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom and Queen Mary University of London, London.
³ Department of Hematology, San Bortolo Hospital, Vicenza.
⁴ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Østfold hospital, Norway and Institute of clinical medicine, University of Oslo, Oslo.
⁵ Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden.
⁶ Universitätsklinikum Jena, Jena.
⁷ Department of Hematology/Oncology, University Children's Hospital Basel, Basel.
⁸ Department of internal medicine, referral center for autoimmune cytopenias in adults, and Clinical investigation center 1436, Toulouse University hospital, Toulouse.
⁹ Hematology Project Foundation, Affiliated to the Department of Hematology, San Bortolo Hospital, Vicenza.
¹⁰ Østfold hospital, Norway and Institute of clinical medicine, University of Oslo, Oslo.
¹¹ Guy's Hospital, London.
¹² European Research Consortium on Immune thrombocytopenia (ERCI), founding member; DSM, Università degli Studi di Trieste, Trieste.
¹³ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Department of Hematology/Oncology, University Children's Hospital Basel, Basel.
¹⁴ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER, Murcia, Spain.
¹⁵ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hospital Universitario de Burgos, Burgos, Spain.
¹⁶ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; ITP Centre and UK Adult ITP registry, Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom and Queen Mary University of London, London.
¹⁷ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Mondor University Hospital, Créteil.
¹⁸ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Imperial College London, London.
¹⁹ European Research Consortium on Immune thrombocytopenia (ERCI), founding member; Hematology Project Foundation, Affiliated to the Department of Hematology, San Bortolo Hospital, Vicenza.

PMID: 40568720
DOI: 10.3324/haematol.2025.287408

Abstract

Not available.

PubMed Disclaimer

LinkOut - more resources

Full Text Sources
- Pagepress Publications

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

Affiliations

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

Authors

Affiliations

Abstract

LinkOut - more resources

Full Text Sources